Literature DB >> 1421529

Cell-growth quantitation methods for the evaluation of antiestrogens in human breast cancer cells in culture.

P T Jain1, J T Pento, D C Graves.   

Abstract

The antiproliferative activity of the antiestrogen, tamoxifen, on the growth of MCF-7 human breast cancer cells was evaluated using the hemocytometric trypan blue exclusion method, [3H]-thymidine incorporation, and a total protein determination. Tamoxifen was evaluated over a concentration range from 10(-9) to 10(-6) M. The hemocytometric trypan blue exclusion method and [3H]-thymidine incorporation were sensitive enough to demonstrate the inhibitory influence of tamoxifen on the proliferation of MCF-7 cells at a concentration as low as 10(-9) M. A very good correlation of these two methods was observed in the submicromolar concentration range of tamoxifen. The total protein determination method was only sensitive enough to detect the antiproliferative influence of tamoxifen at concentrations above 10(-6) M. In conclusion, the [3H]-thymidine incorporation method was found to be effective and much less time consuming than the hemocytometric trypan blue exclusion method for evaluating the antiproliferative effects of antiestrogens in cultured MCF-7 cells. However, when evaluating antiestrogens, which are cell-cycle specific, the results of the [3H]-thymidine incorporation method should be interpreted with caution.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1421529     DOI: 10.1016/1056-8719(92)90042-y

Source DB:  PubMed          Journal:  J Pharmacol Toxicol Methods        ISSN: 1056-8719            Impact factor:   1.950


  2 in total

1.  The influence of a novel cyclopropyl antiestrogen (compound 7a) on human breast cancer cells in culture.

Authors:  P T Jain; J T Pento; R A Magarian
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

2.  Significant alterations in the expression pattern of kallikrein-related peptidase genes KLK4, KLK5 and KLK14 after treatment of breast cancer cells with the chemotherapeutic agents epirubicin, docetaxel and methotrexate.

Authors:  Georgia Papachristopoulou; Maroulio Talieri; Andreas Scorilas
Journal:  Tumour Biol       Date:  2012-10-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.